Adipose tissue expression of 11β-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 8, 2007, Pages 1397-1403

  Espíndola Antunes, Daniela ^a   Kater, Claudio E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Adipose tissue; Cortisol; Cortisone; Cushing's syndrome; Metabolic syndrome; Obesity

Indexed keywords

EID: 38649088252     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000800027     Document Type: Review

References (51)

1. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977;44:924-33.
2. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramires LC, Raul W, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979;49:757-64.
3. Lakshmi V, Monder C. Purification and characterization of the 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 1988;123:2390-8.
4. Low SC, Assaad SN, Rajan V, Chapman KE, Edwards CR, Seckl JR. Regulation of 11β-hydroxysteroid dehydrogenase by sex steroids in vivo: further evidence for the existence of a second dehydrogenase in rat kidney. J Endocrinol 1993;139:27-35.
5. Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004;15:418-24.
6. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3.
7. Bujalska IJ, Kumar S, Hewison M, Stewart PM. A switch in the dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002;87:1205-10.
8. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112:83-90.
9. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1 deficient mice. Diabetes 2004;53:931-8.
10. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137-95.
11. Stewart PM. Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenase and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003;149:163-8.
12. th ed. Philadelphia: Saunders, 2003. pp. 491-539.
13. Lönn L, Kvist H, Ernest I, Sjöström L. Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome. Metabolism 1994;43:1517-22.
14. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. J Clin Endocrinol Metab 1988;67:1122-8.
15. Walker BR. Extra-adrenal regeneration of glucorticoids by 11β-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy petitioning. Proc Nutr Soc 2007;66:1-8.
16. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
17. Ljung T, Andersson B, Bengtson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose response study. Obes Res 1996;4:277-82.
18. Jessop DF, Dallman MF, Flaming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001;86:4109-14.
19. Pasquali R, Ambrosi B, Armanini D, Cavagnine F, Uberti ED, Del Rio G, et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab 2002;87:166-75.
20. Ljung T, Holm G, Friberg P, Bjorn A, Bengtsson B-A, Svensson J, et al. The activity of the hypothalamic-pituitary-adrenal-axis and the sympathetic nervous system in relation to waist-hip circumference in men. Obes Res 2000;8:487-95.
21. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, et al. The hypothalamic pituitary adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993;77:341-6.
22. Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH. Association of 24h-cortisol production rates, cortisol binding globulin, and plasma free cortisol levels with body composition, leptin levels, and aging in adult men women. J Clin Endocrinol Metab 2004;89:281-7.
23. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-21.
24. Masuzaki H, Paterson JM, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
25. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, et al. Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Nat Acad Sci USA 2004; 101:7088-93.
26. Morton NM, Ramage L, Seckl JR. Down-regulation of adipose tissue 11β-hydroxysteroid dehydrogenase type 1 by high fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 2004;145:2707-12.
27. Alberts P, Engblom L, Eddling N, Forsgren M, Klingstron G, Larsson C, et al. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreased blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45:1528-32.
28. Hermanowski-Vosatka A, Blakovec JM, Cheng K, Chen HY, Hernandez, Koo GC, et al. 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202:517-27.
29. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2001;87:2701-5.
30. Wake DJ, Rask E, Livingstone, Sodeberg S, Olsson T, Walker BR. Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003;88:3983-8.
31. Lindsay RS, Wake JW, Saraswathy N, Bunt J, Livingstone DEW, Permana PA, et al. Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88:2738-44.
32. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, et al. Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004;12:9-17.
33. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM. Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002;87:5630-5.
34. Sandeep TC, Andrew R, Homer NZM, Andrews RC, Smith K, Walker BR. Increased in vivo generation of cortisol in adipose tissue in human obesity and the effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005;54:872-9.
35. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, et al. Regulation of the expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue-specific induction by cytokines. Endocrinology 2001;142:1982-9.
36. Andrew R, Philips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998;83:1806-9.
37. Stewart PM, Boulton A, Kumar S, Clark PMS, Shackleton CHL. Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
38. Franks PW, Knowler WC, Nair S, Koska J, Lee Y-H, Lindsay RS, et al. Interaction between an 11β-HSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension 2004;44:681-8.
39. Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus C, et al. 11β-hydroxysteroid dehydrogenase type 1: Genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia 2004;47:1088-95.
40. Draper N, Echwald SM, Lavery GG, Walker EA, Fraser R, Davies E, et al. Association studies between microsatellite markers within the gene encoding for human 11β-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J Clin Endocrinol Metab 2002;87:4984-90.
41. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscoro M, Mantero F, et al. Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 2006;155:435-41.
42. Espíndola-Antunes D, Goto EM, Guimarães AO, Pesquero JB, Silva-Júnior JA, Kater CE. Quantitative mRNA expression of 11β-hydroxysteroid dehydrogenase type 1 and glucocorticoid receptor alpha in visceral adipose tissue of patients with Cushing's syndrome and obese and non-obese controls. Proc Endocr Soc Meeting 2007; [abstract].
43. Tomlinson JW, Moore JS, Clarck PMS, Holder G, Shakespeare L, Stewart PM. Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 2004;289:2711-6.
44. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66.
45. Wake DJ, Stimson RH, Tam GD, Homer NZM, Andrew R, Carpe F, et al. Effects of peroxisome proliferator-activated receptor α and γ agonists in 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 2007;92:1848-56.
46. Basu R, Singh R, Basu A, Johson CM, Rizza RA. Effect of nutrient ingestion on total-body and splanic cortisol production in humans. Diabetes 2006;55:667-74.
47. Wake DJ, Homer NZD, Andrew R, Walker BR. Acute in vivo regulation of 11β-hydroxysteroid dehydrogenase type 1 by insulin and intralipid infusions in humans. J Clin Endocrinol Metab 2006;91:4682-8.
48. Harris HJ, Kotelevtsev Y, Mullings JJ, Seckl JR, Holmes MC. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary- adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 2001;142:114-20.
49. Stulnig TM, Waldhausl W. 11β-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 2004;47:1-11.
50. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80:3155-9.
51. Andrews RC, Rooyackers O, Walker BR. Effects of the 11β- hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-91.